Palmitoylation stabilizes PD-L1 to promote breast tumor growth
Dear Editor,PD-L1 is a well-known transmembrane protein,which is highly expressed on many types of cancer cells.By binding to its receptor PD-1 on T cells,PD-L1 significantly inhibits T cells activation and activity,and thus plays a pivotal role in driving the escape of tumor cells from immune surveillance.1 Antibody blockade of PD-L1/PD-1 interaction has revolutionized cancer therapy with promising clinical outcomes in many cancer types,including melanoma,lung cancer,bladder cancer,colorectal cancer,and renal-cell cancer.2 However,in some others such as prostate cancer,ovarian cancer,and breast cancer,the response rate of PD-L1/PD-1 antibody therapy is less satisfactory.3 Recent studies have shown that PD-L1 can be regulated by post-translational regulations such as ubiquitination,4 phosphorylation and glycosylation,5 providing opportunity for marker-guided effective combinational therapy with immune checkpoint therapy.
29
This work was funded in part by the following: National Institutes of HealthCCSG CA016672, R01 CA211615, R01 Al116722, U01 201777;Cancer Prevention & Research Institutes of TexasRP160710;National Breast Cancer Foundation, Inc;Breast Cancer Research FoundationBCRF-17-069;Patel Memorial Breast Cancer Endowment Fund;The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund;Center for Biological Pathways;The University of Texas MD Anderson Cancer Center Odyssey Fellowship Program
2019-03-08（万方平台首次上网日期，不代表论文的发表时间）
共4页
83-86
